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Background: Therapeutic gene transfer is currently being evaluated as a potential therapy for inflammatory bowel
disease. This study investigates the safety and therapeutic benefit of a locally administered lentiviral vector encoding
murine interleukin-10 in altering the onset and relapse of dextran sodium sulfate induced murine colitis.
Methods: Lentiviral vectors encoding the reporter genes firefly-luciferase and murine interleukin-10 were administered
by intrarectal instillation, either once or twice following an ethanol enema to facilitate mucosal uptake, on Days 3
and 20 in Balb/c mice with acute and relapsing colitis induced with dextran sulfate sodium (DSS). DSS colitis was
characterized using clinical disease activity, macroscopic, and microscopic scores. Bioluminescence optical imaging
analysis was employed to examine mucosal lentiviral vector uptake and transgene expression. Levels of tumor
necrosis factor-α and interleukin-6 in homogenates of rectal tissue were measured by ELISA. Biodistribution of the
lentiviral vector to other organs was evaluated by real time quantitative PCR.
Results: Mucosal delivery of lentiviral vector resulted in significant transduction of colorectal mucosa, as shown by
bioluminescence imaging analysis. Lentiviral vector-mediated local expression of interleukin-10 resulted in significantly
increased levels of this cytokine, as well as reduced levels of tumor necrosis factor-α and interleukin-6, and significantly
reduced the clinical disease activity, macroscopic, and microscopic scores of DSS colitis. Systemic biodistribution of
locally instilled lentiviral vector to other organs was not detected.
Conclusions: Topically-delivered lentiviral vectors encoding interleukin-10 safely penetrated local mucosal tissue and
had therapeutic benefit in this DSS model of murine colitis.
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Inflammatory bowel disease (IBD), comprising Crohn’s
disease (CD) and ulcerative disease (UC), is thought to
result from abnormal interactions between gut associ-
ated lymphoid tissue and enteric microflora. This abnor-
mal mucosal immune response is probably facilitated by
defects in epithelial barrier function [1]. Interleukin (IL)-* Correspondence: imcgowan@pitt.edu
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article, unless otherwise stated.10 plays a crucial role in mucosal immunoregulation,
inhibiting aspects of both the innate and cell mediated
inflammatory response [2]. IL-10 has broad immunoreg-
ulatory activity and acts to suppress intestinal inflamma-
tion on several levels. Gene-targeted IL-10 knockout
mice (IL-10−/−) and IL-10 receptor 2 deficient mice
spontaneously develop an enterocolitis by 2–3 months
of age with multifocal inflammatory lesions throughout
the gastrointestinal tract [3]. In addition, mutations in
the gene encoding the IL-10 receptor subunit proteins
have been found in IBD patients [4]. IL-10 suppresses
the release of many other proinflammatory cytokinesntral Ltd. This is an Open Access article distributed under the terms of the
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(TNF-α), IL-1, IL-6, and IL-8. Finally there is strong evi-
dence that IL-10 acts to promote the differentiation and
augment the activity of regulatory T cells [5].
Administration of systemic IL-10 is sufficient to inhibit
inflammation and abrogate experimental colitis models
[6,7]. However, clinical trials in Crohn’s disease have
shown that, although daily systemic IL-10 injections are
safe and well tolerated, they have minimal therapeutic
efficacy [8,9]. One explanation for these disappointing
results is that daily systemic therapy does not deliver ad-
equate mucosal levels of IL-10 that would be needed to
control proinflammatory responses associated with ac-
tive CD. Thus, strategies that result in greater mucosal
exposure to IL-10 in the gastrointestinal tract may prove
effective in treating IBD.
Several IL-10 delivery systems targeting the gastro-
intestinal mucosa have been reported; rectal administra-
tion using an adenovirus vector [10], oral delivery using
non-pathogenic bacteria (Lactococcus lactis) [11], and
oral nanoparticles [12]. Recently, we demonstrated the
ability of a vesicular stomatitis virus envelope glycopro-
tein (VSV-G) pseudotyped lentiviral vector (LV) to infect
colonic mucosal tissue via the apical surface in vivo, after
intraluminal instillation per rectum in a healthy murine
model and ex vivo in a human intestinal explant system
[13]. In this study, we tested whether efficient local gene
transfer can be accomplished using LV expressed murine
IL-10 (mIL-10) in a murine colitis model.
Methods
Vector construction and preparation
The pRRLsin-hCMV-fLuc vector was constructed by in-
sertion of the firefly Luciferase (fLuc) gene [14], and the
pRRLsin-hCMV-mIL10 vector by insertion of the mIL-
10 coding sequence from plasmid pORF5-mIL-10 (Invi-
voGen, San Diego, CA, USA), respectively, into the
multiple cloning site (MCS) of pRRLsin-hCMV-MCS-
pre, a third-generation, self-inactivating LV construct
provided by Dr. Luigi Naldini (San Rafaelle Telethon In-
stitute, Milan, Italy) [15]. All constructs were recon-
firmed by restriction digestion and DNA sequencing
analysis. Vesicular stomatitis virus glycoprotein envelope
(VSV-G)-pseudotyped LV virus was produced in 293 T
cells using a third-generation packaging system as previ-
ously described [16]. LV titers were determined by HIV-
1 p24 ELISA (Coulter Immunotech, Miami, FL, USA)
and expressed as p24 equivalent units (ng/ml).
Cell culture in vitro gene transfer study
Three human colonic cancer cell lines of epithelial origin
(CaCo-2, LoVo, and WiDr) were obtained from the
American Type Tissue Collection (ATCC, Manassas, VA,
USA) and grown at 37°C in 5% CO2 in Dulbecco’smodified Eagle’s medium, Ham’s F12K medium, or RPMI
1640, respectively. All media were supplemented with 10%
fetal bovine serum and 1% penicillin-streptomycin. Trans-
ductions were done using media containing polybrene
(8 μg/ml) (Sigma, St. Louis, MO, USA) to enhance gene
transduction [17]. Each transduction was carried out with
1 × 105 cells. To assess the mIL-10 productive capacity of
the LV constructs, 100 ng p24 of the LV-mIL-10 (equiva-
lent to a biological infectious titer of 5 × 106 transducing
units on the standardized cell line HEK-293 T [18]) was
added to monolayer cultures of the three specified cell
lines at a multiplicity of infection (MOI) of 0.1, 1.0 or 10
(ratio of virus to cell number). Transduction was per-
formed with the viral solution at 37°C for 12 hours
followed by a change of medium and a second 24 hour
incubation. After the 36 hour transduction period, super-
natants were collected, filtered, and stored for batch quan-
tification of mIL-10 level by ELISA.
Preliminary treatment to enhance mucosal delivery of
the LV
Mucosal pretreatment with a 20% ethanol (EtOH) enema
was used to enhance gene delivery into the colonic mu-
cosa. Female Balb/c mice (weight: 19–23 grams, age: 6–8
weeks) (Charles River Laboratories, Inc., Wilmington,
MA, USA) were housed in a specific pathogen-free envir-
onment prior to LV exposure. All in vivo studies were per-
formed under the appropriate guidelines and with the
approval of the UCLA Animal Research Committee.
Ex vivo bioluminescence imaging
Ex vivo bioluminescence imaging (BLI) of transduced
tissue from gastrointestinal (GI) organs was used to as-
sess LV-guided gene transfer into the colonic mucosa.
Two days following topical exposure to a LV expressing
fLuc, GI tract organs from each group were harvested en
bloc, bathed and imaged using a cooled charge-coupled
device (CCD) system (Xenogen IVIS, Caliper Life Sci-
ences, Alameda, CA, USA) where gray-scale background
photographic images of the tissues were overlaid with
color images of bioluminescent signals (Living Image
and IGOR-PRO image analysis software, Wave Metrics,
Portland, OR, USA).
LV-mIL-10 treatment effect on dextran sulfate sodium
colitis
Colitis was induced by exposure to 3% (w/v) dextran sul-
fate sodium (DSS; molecular weight 36-50 kDa; ICN
Pharmaceutical, Costa Mesa, CA) administered orally
which reproducibly produces histologic inflammation
mainly in the left colon [19,20]. Each mouse received
2 cycles of DSS oral treatment with each cycle consisting
of 7 continuous days with DSS added to the drinking
water followed by a 10 day period without DSS.
Matsumoto et al. BMC Gastroenterology 2014, 14:68 Page 3 of 9
http://www.biomedcentral.com/1471-230X/14/68For this experimental design, mice were divided four
groups (n = 8 mice/group): (i) non-exposed, healthy con-
trols (NC), (ii) mock-exposed (plasmid complex solution
without the mIL-10 vector), (iii) once-exposed treatment
group (LV(1)) and (iv) twice-exposed treatment group
(LV(2)). LV-mIL-10 was given on day 3 of each of the
two DSS cycles. Mice were anesthetized with an intra-
peritoneal injection of 10 mg/kg xylazime and 100 mg/kg
ketamine. Two hours following the preliminary EtOH
enema treatment, 100 μl of 1000 ng/p24 viral solution was
atraumatically injected intrarectally via a 1.2 mm diameter
catheter. Mice were sacrificed on Day 10 (n = 4) or 32
(n = 4), following each DSS exposure.
Clinical, macroscopic and histologic assessments
The health status of all treated mice was followed closely
and all mice were weighed 3 times/week. The clinical
disease activity score (CDA; scores range from 0–4) was
assessed using a previously published index incorporat-
ing body weight, stool consistency and occult blood [19].
Postmortem, the entire colon was removed from the
cecum to the anus, flushed with saline, and placed with-
out tension on cellulose [19,20] where it was fixed in 4%
paraformaldehyde overnight. Subsequently, the tissue
was placed in 30% sucrose/PBS for 2 hrs, embedded in
OCT compound with serial 5.0-μm-thick frozen sections
sliced from the block and stained with hematoxylin and
eosin (H&E) for histologic scoring (range: 0–6) by a
pathologist, blinded to sample groupings. Macroscopic
colonic damage score was assessed during colon removal
as previously reported [21] with minor modifications.
The scoring, with ranges from 0–9, included scales for0
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Figure 1 Quantification of in vitro transduction of vesicular stomatitis
mouse interleukin 10 (mIL10) in colonic cell lines. Cell line production
(0.1 ng/p24, 1.0 ng/p24, 10 ng/p24) for transfection are shown. Each exper
ELISA. All values were expressed as mean ± SD. *p < 0.05 compared with thdegrees of tissue adhesion, presence of ulceration, and
wall thickness. A combined score was used next to as-
sess injury from the macroscopic and the histologic
grading [22]. The scores for cell infiltration and tissue
damage were added, resulting in a combined histologic
score ranging from 0 to 6.
Cytokine production
As described previously, tissue was homogenized in nine
volumes of Greenberger lysis buffer (300 mM NaCl,
15 mM Tris HCl, 2 mM MgCl2, 2 mM, Triton (X-100),
pepstatin A, leupeptin, aprotinin (all 20 ng/ml), pH 7.4)
[23,24]. Tissue was lysed for 30 min on ice followed by
two centrifugations at 14,000 g for 10 min each. Homog-
enates were stored at −20°C until further use. TNF-α,
IL-6 and IL-10 protein concentrations (pg/mL) were
measured by ELISA (R&D Systems, Abingdon, England).
Biodistribution analysis by real-time quantitative PCR
(RT-qPCR)
To determine the lentiviral DNA copy number within
the colorectal tissues following topical exposure, we per-
formed qPCR. Genomic DNA was isolated from mouse
colonic tissue using DNeasy Tissue Kit (Qiagen, Inc.,
Valencia, CA, USA). Quantification of vector copy num-
bers was performed in 25 μL reactions containing
300 ng genomic DNA (equivalent to 5 × 104 genomes)
using TaqMan qPCR assay to detect the HIV-1 pack-
aging sequences as a universal primer [25]. Amplifica-
tions were carried out in an ABI PRISM 7700 sequence
detector (Perkin Elmer, Wellesley, MA, USA). After the
initial denaturation step (10 min at 95°C), amplificationO2 LoVo
Dose of 
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(ng/p24)
1
10 0.
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*
virus G protein (VSV-G)-pseudotyped lentivirus (LV) encoding
of mIL-10 in pg/ml following three titered infectious doses of LV
iment collected took triplicate supernatant, and measured IL-10 by
e results of 0.1 ng p24 LV transduction.
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at 60°C. To calculate the copy number in the samples, a
reference curve was prepared by amplifying serial dilu-
tions of a LV-CMV-Luc plasmid in a background of gen-
omic DNA obtained from untransduced murine colon.
Genomic DNA from the PC3 cell line, a human prostatePBS + LV
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Figure 2 Optimization of mucosal LV transfection. Ex vivo
Bioluminescence imaging (BLI) analyses. Ex vivo BLI quantification
and analyses of GI tract following intrarectal administration of LV
expressing firefly luciferase (fLuc) on either colon with (a) PBS only,
(b) with PBS followed by 3% DSS, (c) with 20% EtOH only, or
(d) with 20% EtOH followed by 3% DSS. This pseudocolor image,
superimposed on a gray scale reference image, uses color (blue:
least intense; red: most intense) to illustrate signal strength.
Abbreviations: Sto: stomach; Si: small intestine; Co: colon; Ce: Cecum;
Re: rectum; Li: liver; Ki: kidney; Sp: spleen. (e) quantifies photon
emission (p/s/cm2/sr) in the distal colon. *p < 0.05.cancer cell line, transduced with LV-GFP was used as a
positive control. PC3 cells were shown to have 100%
transduction by flow cytometry and as these cells are
hyperploid, the vector copy number in 300 ng of PC3
genomic DNA was quantitated as approximately 16,000
(data not shown).
Statistical analysis
All values were expressed as means ± SD. Comparisons
between groups were made using the student t-test and
the Mann–Whitney U test. A p value of less than 0.05
was considered statistically significant. Statistical analysis
was performed using Graph Pad Prism (Version 4.00 for
Macintosh; GraphPad Software, San Diego, CA, USA).
Results
IL-10 production in vitro
The level of IL-10 production following transduction
with the mIL-10 LV was 881 pg/ml in WiDr cells,
205 pg/ml in CaCo-2 cells, and 153 pg/ml in LoVo cells.
All cell lines produced measurable mIL-10, with expres-
sion levels increasing in a vector dose-dependent manner
(Figure 1).
Bioluminescent imaging of LV transfer
BLI analysis of the entire removed colon was used to
quantify the regional distribution and levels of gene
transduction by LV encoding fLuc following various de-
livery protocols. A strong positive signal was seen only
in the distal colon, adjacent to the rectum, in 8/8 (100%)Figure 3 The time course of clinical changes of 3% dextran
sulfate sodium (DSS) colitis with/without lentivirus vector (LV)
encoding mouse interleukin 10 (mIL-10). Mice were treated with
3% DSS from Days 1–7 and 18–24. Four treatment groups (n = 8
mice per group) were (i) a control group who did not receive DSS
or an LV (NC), (ii) a group who received DSS + a mock plasmid
control (mock), (iii) a group who received DSS + a single dose of the
mIL-10 LV on Day 3 (LV(1)), and (iv) a group who received DSS +
doses of the mIL-10 LV on Days 3 and 20 (LV(2)).
ab
c
Figure 4 (See legend on next page.)
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Figure 4 Clinical, macroscopic, and histopathological changes following treatment with lentivirus vector encoding mouse interleukin
10 (mIL-10). (a) CDA score was monitored 3 day per a week. Each point represents the mean ± SD. Balb/c mice received Mock or LV encoding
mIL-10 (LV mIL-10) once or twice by rectal administration. There is a significant difference between Mock and both LV mIL-10 (1) and (2), however
no difference between LVmIL-10(1) and (2) on Days 10 and 24. All values were expressed as mean s ± SD. Statistically significant differences are
shown. *P < 0.05. (b) Changes in macroscopic colonic damage scores of 3% DSS colitis treated with LV encoding mIL-10. Macroscopic colonic
damage score of mock-treated, LV once-treatment/DSS exposure group (LV(1)) or LV twice-treatment/DSS exposure group (LV(2)) compared to
no treatment groups (n = 8/group) are shown for each of the two DSS exposures on Day 10 or Day 32. All values were expressed as mean ± SD.
Statically significant differences are shown. *p < 0.05. (c) Changes in histologic scoring of 3% DSS colitis treated by LV encoding mIL-10. The
degree of histological injury following DSS exposure on Day 10 and Day 32 are shown for mock-treated, LV once-treatment/DSS exposure group
(LV(1)) or LV twice-treatment/DSS exposure group (LV(2)) compared to no treatment groups (n = 8/group). All values were expressed as mean ±
SD. Statically significant differences are shown. *p < 0.05.
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DSS colitis model (Figure 2a-d). Significantly higher bio-
luminescent light signals were observed after LV delivery
with 20% EtOH than with saline (PBS) control pre-
treatment in the 3% DSS colitis groups, indicating a
significantly higher level of transduction with ethanol
pre-treatment (91,260 ± 23,060 versus 8881 ± 1655 pho-
tons/sec) (Figure 2e).
Impact of LV mIL-10 gene therapy on DSS colitis severity
DSS-induced mucosal injury was quantified by clinical,
macroscopic and histologic scores. All three indices were
significantly improved following exposure to LV produ-
cing mIL-10. Figure 3 shows the time course of clinical
disease activity (CDA) by study arm. The mock exposed
group showed two peaks of severity using the CDA
score, on Days 9 and 24. LV gene therapy significantly
suppressed both of these peaks overall as well as in each
of the sub-categories (weight loss, stool consistency, rec-
tal bleeding) (Figure 4a). Macroscopic (tissue adhesion,
ulceration, wall thickness) (Figure 4b) and histologicalDay 10
Day 32
MockNC
a b
e f
Figure 5 Histopathology sections of DSS colitis treated with LV encod
shown following DSS exposure at Day 10 (a, b, c, d) or Day 32 (e, f, g, h). No
showed the expected severe colonic inflammation on both Days 10 and 32. T
per DSS cycle (LV(1)) or twice/cycle (LF(2)), showed reduction in inflammation(infiltration of cells, tissue damage) (Figure 4c, Figure 5a-h)
scores were also each significantly suppressed by LV gene
therapy compared to the mock treated mice.
Changes in mucosal cytokine proteins in DSS colitis tissue
treated by LV mIL-10
Neither IL-10 nor IL-6 were detectable in the colonic
homogenates from the NC mice. TNF-α was present at
low levels (0.7 ± 0.3 pg/ml at Day 10 and 0.6 ± 0.4 pg/ml
at Day 32). In contrast, all three cytokines were present
in the mock-treated group of mice, which were exposed
to DSS but did not receive LV-mediated gene therapy
(Table 1). Mice receiving one or two exposures to the
IL-10 LV had significantly higher mucosal tissue levels
of IL-10 than either the control or mock-treated groups.
In mice receiving one exposure to the IL-10 LV, levels of
IL-10 were 18.1 ± 3.9 pg/ml at Day 10 and 12.9 ±
12.1 pg/ml at Day 32. In the mice receiving two expo-
sures to the IL-10 LV, levels of IL-10 were 15.9 ± 3.7 pg/
ml at Day 10 and 14.3 ± 0.7 pg/ml at Day 32. Interestingly,
TNF-α was reduced in all the mice receiving the IL-10 LV.VSV-G LV(1) VSV-G LV(2)
c d
g h
ing mIL-10. Representative sections of each treatment groups are
rmal controls for each are shown in (a) and (e). Mock-treatment group
reatment with LV encoding mIL-10, regardless of whether given once
on both Days 10 and 32. (H & E stain; magnification: 200×).
Table 1 Cytokine levels in mucosal tissue
Cytokine DSS day NC Mock LV(1) LV(2)
IL-10 10 ND 3.9 ± 1.6 18.1 ± 3.9* 15.9 ± 3.7*
32 ND ND 12.9 ± 12.1 14.3 ± 0.7
TNF-α 10 0.7 ± 0.3 25.4 ± 9.4 11.5 ± 5.4 3.9 ± 1.8
32 0.6 ± 0.4 15.2 ± 6.5 3.5 ± 1.4* 3.9 ± 2.9
IL-6 10 ND ND ND ND
32 ND 14.5 ± 1.3 ND ND
*p <0.05 compared to mock infection.
ND; Not detected.
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TNF-α were 11.5 ± 5.4 pg/ml at Day 10 and 3.5 ± 1.4 pg/
ml at Day 32. In the mice receiving two exposures to the
IL-10 LV, levels of TNF-α were 3.9 ± 1.8 pg/ml at Day 10
and 3.9 ± 2.9 pg/ml at Day 32. IL-6 was undetectable in all
of the mice receiving the IL-10 LV.
Biodistribution study by qPCR analysis
Biodistribution analysis by qPCR showed evidence of
transduction in the colorectum in all mice treated with
3% DSS upon local LV administration following 20%
EtOH (Figure 6) but in no other areas of the gastrointes-
tinal tract (rest of colon, small intestine, stomach or
liver). Transduction levels in the colorectum were on
the order of 2 to 3%. No gene expression was identified
in any extra-gastrointestinal tissue examined (kidney,
spleen, lung, heart, brain, bone marrow). These data
confirm that topical administration of LV enabled local
tissue transduction but minimal spread to other regions
within the gastrointestinal tract, and no detectable extra-
intestinal spread.10
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Figure 6 Analysis of LV biodistribution by real-time quantitative
PCR (RT-qPCR). Genomic DNA was isolated from mouse colonic tissue
and vector copy number was quantified using TaqMan qPCR assay to
detect the HIV-1 packaging sequences. Genomic DNA from the PC3
cell line, a human prostate cancer cell line, transfected with LV-GFP
was used as a positive control.Discussion
In this study, we have demonstrated for the first time
that an LV could be used as a novel gene delivery system
for the treatment of DSS colitis. Topical gene therapy
using a LV encoding mIL-10 was found to suppress not
only the development but also the relapse of the colitis.
The LV platform is efficient and provides a unique gene
transfer system with a number of features that differenti-
ate it from other topical gene therapy approaches that
have been evaluated for the treatment and prevention of
experimental models of colitis.
Adenovirus vectors [10,24,26-29] and cationic lipids
complexed to immunoregulatory genes [30], have re-
ported efficacy in the treatment of murine colitis. How-
ever, a major disadvantage of these systems is that the
transgene expression is transient since genes are trans-
duced into mucosal epithelial cells that only live for
about 2–3 days. Alternatively, an approach using Lacto-
coccus lactis only transiently increased mucosal IL-10
concentration because the bacteria did not colonize the
intestine [11,31]. Ex vivo retroviral gene transfer of CD4+
T cells with IL-10 did not have any therapeutic benefit in
acute colitis of immunocompetent mice, though it did
prevent induction of colitis in a transfer colitis model
using immunodeficient mice [32].
Here we chose to evaluate whether a LV encoding IL-
10 was effective in treating or preventing DSS induced
murine colitis for three reasons. Firstly, this colitis model
induces profound epithelial barrier disruption that might
facilitate LV transduction and access to the lamina pro-
pria [19]. Secondly, this DSS colitis model shows severe
inflammation in the distal colon [19,20,22], the area
known to have maximal LV transduction. Finally, muco-
sal CD4+ cells, an important target of LV transduction,
also play a critical role in the pathogenesis of IBD colitis
[33]. Within the DSS model, increases in mucosal CD4+
T cells occur in a dose dependent fashion such that with
5% DSS induced colitis is associated with significantly
more CD4+ T cells compared to 3% DSS colitis [34]. Sup-
porting our hypothesis, LV expressed mIL-10 showed effi-
cacy against acute and relapsing murine DSS colitis.
Notably, we found that topical delivery of a LV encod-
ing IL-10 could suppress not only the development but
also prevent relapse of DSS colitis. This is a unique fea-
ture of the LV approach and has not been seen in other
traditional vector systems. We suggest that the reason
for this property might relate to the ability of the LV to
transduce both colonic mucosal epithelial and mucosal
CD4+ T cells following rectal administration [13]. Muco-
sal CD4+ T cells play a dominant role in controlling
gastrointestinal mucosal inflammation, especially regula-
tory CD4+ T cells through secretion of anti-inflammatory
cytokines such as IL-10 [5,7]. Interestingly, although not
statistically significant, administration of two vector doses
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cacy than a single dose. In this context, it is notable that
IL-10 levels were comparable between the single dose and
double dose groups, perhaps due to feedback down regu-
lation of endogenous IL-10 in response to vector-derived
IL-10. Alternative explanations might include the induc-
tion of antibodies or other immunological processes that
reduce the efficiency of lentiviral infection and or bio-
logical availability of IL-10 in the mucosal tissue. Add-
itional studies are warranted to examine whether higher
vector concentrations or frequency of administration
might achieve further benefit.
In addition to the barrier disruption caused by DSS
colitis, 20% ethanol pre-treatment was also required for
optimal LV transduction, perhaps by helping to dissolve
or wash away physical barriers obstructing vector access
to the cellular surfaces of the mucosal epithelium. While
20% ethanol pre-treatment in itself induces no mucosal
inflammation, in the presence of 3% DSS-induced colitis
we obtained transduction levels comparable to those ob-
served in our previous studies using 50% ethanol pre-
treatment to enhance vector transduction efficiency in
the absence of pre-existing mucosal inflammation [13].
Furthermore, similar approaches have been tested both
pre-clinically and in clinical trials, e.g., using ethanol or
surfactants to improve transduction efficiency of vectors
instilled into the bladder, and so this approach has po-
tential for clinical translation in IBD.
There are a number of limitations to our study. Use of
additional control groups such as an IL-10 plasmid or
lentiviral vector without the IL-10 insert could have pro-
vided insight as to the independent contribution of the
lentiviral vector and the IL-10 on the subsequent modu-
lation of mucosal infection. In addition we did not meas-
ure plasma IL-10 or other immunological parameters
that could have provided explanations as to why a sec-
ond dose of the LV did not appear to provide benefits
above or beyond those seen with a single dose of LV.
Conclusion
In conclusion, we have demonstrated that topical gene
therapy using a VSV-G LV vector to deliver therapeutic
levels of IL-10 could have promise as a novel therapy for
IBD colitis. Follow-up studies are needed to determine
whether this vector system would be effective in treating
other models of murine colitis such as the IL-10 knock
out model of murine colitis [3].
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